Table 3.
Study | * BRAF status exon 15 codon 600 | n | Treatment | RR |
PFS |
OS |
|||
---|---|---|---|---|---|---|---|---|---|
% | p value $ | Median (months) | p value $ | Median (months) | p value $ | ||||
Di Nicolantonio et al. [2008] | BRAF mut | 11 | (Cetuximab or panitumumab) ± chemotherapy | 0 | 0.029 | NR | 0.011 | NR | <0.0001 |
BRAF wt | 68 | 3 | |||||||
Laurent-Puiget al. [2009] | BRAF mut | 5 | Cetuximab ± chemotherapy | 0 | 0.063 | 1.8 | 0.001 | 6.5 | 0.001 |
BRAF wt | 110 | 46.8 | 7.2 | 14.8 | |||||
European consortium De Roock et al. [2010] | BRAF mut | 24 | Cetuximab ± chemotherapy | 8.3 | 0.0012 | 1.8 | <0.0001 | 6.0 | <0.0001 |
BRAF wt | 326 | 38.0 | 6.0 | 12.5 | |||||
Bokemeyer et al. [2012] | BRAF mut | 32 | Chemotherapy/cetuximab | 21.9 | 0.46 | 7.1 | 0.23 | 14.1 | 0.076 |
38 | Chemotherapy | 13.2 | 3.7 | 9.9 | |||||
BRAF wt | 349 | Chemotherapy/cetuximab | 60.7 | <0.0001 | 10.9 | <0.0001 | 24.8 | 0.048 | |
381 | Chemotherapy | 40.9 | 7.7 | 21.1 | |||||
Tveit et al. [2012] | BRAF mut | 55 | NA | 20 | <0.001 | 5.1 | <0.001 | 9.5 | <0.001 |
BRAF wt | 402 | 50 | 8.3 | 22.0 | |||||
PRIME Douillard et al. [2013] | BRAF mut | 24 | FOLFOX4/panitumumab | NA | NA | 6.1 | 0.12 | 10.5 | 0.76 |
29 | FOLFOX4 | 5.4 | 9.2 | ||||||
BRAF wt | 228 | FOLFOX4/panitumumab | NA | NA | 10.8 | 0.002 | 28.3 | 0.02 | |
218 | FOLFOX4 | 9.2 | 20.9 | ||||||
20050181 Peeters et al. [2014] | BRAF mut | 22 | FOLFIR/panitumumab | NA | NA | 2.5 | 0.34 | 4.7 | 0.20 |
23 | FOLFIRI | 1.8 | 5.7 | ||||||
BRAF wt | 186 | FOLFIR/panitumumab | NA | NA | 6.9 | 0.006 | 18.7 | 0.15 | |
190 | FOLFIRI | 5.5 | 15.4 |
All RAS wildtype. $Compared to row immediately below.
Chemo, chemotherapy; EGFR, epidermal growth factor receptor; NA, not available; NR, not reached; mut, mutation; OS, overall survival; PFS, progression-free survival; RR, relative risk; wt, wildtype.